摘要
背景:本研究旨在评估机器人辅助胸腔手术(RATS)治疗非小细胞肺癌(NSCLC)的安全性和治疗效果。研究设计和方法:检索了PubMed、EMBASE、Cochrane图书馆、Web of Science、CNKI、万方、VIP和CBM,从数据库开始到2022年5月1日。使用Newcastle-Ottawa Scale (NOS)进行质量评估,并使用RevMan (5.4版)进行Meta分析。结果:共纳入19篇文献,包含228,947名患者。与VATS相比,RATS的术中失血较少,淋巴结清扫较多,中间开胸的情况较少,胸腔引流管停留时间较短,术后并发症较少,但费用较高。两组在手术时间、术后总引流量和术后住院时间方面没有明显差异。结论:结果表明,RATS具有术中失血少、组织损伤小、恢复快等优点。在治疗临床非小细胞肺癌时,RTAS是安全可行的。
Background: This study aimed to evaluate the safety and therapeutic effect of robot-assisted tho-racic surgery (RATS) for non-small cell lung cancer (NSCLC). Research design and methods: PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, WanFang, VIP, and CBM were searched from da-tabase inception to 1 May 2022. The Newcastle-Ottawa scale (NOS) was used to conduct quality as-sessments, and RevMan (Version 5.4) was used to perform the meta-analysis. Results: A total of 19 publications involving 228,947 patients were included. RATS was associated with less intraopera-tive blood loss, more lymph node dissection, fewer cases of intermediate chest opening, shorter chest drain retention time, and fewer postoperative complications but higher costs compared with VATS. There were no significant differences between the two groups in terms of operative time, total postoperative drainage volume, and postoperative hospital stay. Conclusions: The available evi-dence indicates that the RATS has the advantages of less intraoperative blood loss, minor tissue damage, and quick recovery. In treating clinical non-small cell lung cancer, the RTAS is safely feasi-ble.
出处
《临床医学进展》
2023年第5期8325-8339,共15页
Advances in Clinical Medicine
